Page 2 - Indian Pharma Companies

Short-term painkiller? Pharma Inc gets a breather from US tariffs

Tariff worries, raw material costs still ail sector

'Scenario building' in Indian Pharma Inc ahead of US tariff announcement

Pharmaceutical products have been on the radar of US President Donald Trump, who has indicated that tariffs of up to 25 per cent could be imposed on this category

Will US tariffs succeed in lifting the veil on India's drug safety problem?

Over 30 per cent of Indian pharma exports go to the US, and it provides an even larger proportion of earnings

CDSCO asks MSME pharma firms to apply online for Schedule M extension

This comes after the health ministry had on February 11 formally extended the deadline for implementing the revised Schedule M by one year for pharma companies with an annual turnover below Rs 250 cr

India pharma exports surge 9%, outpacing global average, says report

India has also surpassed the US in the number of FDA-registered generic manufacturing sites

Analysts bullish on Lupin after Q3; share pops 6%; Goldman Sachs ups target

Domestic, as well as global brokerages are optimistic about Lupin's future, citing strong earnings visibility and a promising product pipeline

India's pharma exports set for 10x growth, targeting $350 billion by 2047

Indian biosimilar exports, presently valued at $0.8 billion, are expected to grow fivefold to $4.2 billion by 2030 and reach $30-35 billion by 2047

Indoco Remedies drops 4% on weak Q3 performance; revenue falls 11% YoY

Indoco Remedies share dropped after the company reported a weak set of numbers in the December quarter of financial year 2025 (Q3FY25)

Small, medium-sized pharma firms gear up to comply with revised Schedule M

Pharma groups had wanted two year extension, will raise concerns with govt

Indian pharma improves compliance with USFDA; fewer OAI cases in 2024

Recent USFDA data reveals a decline in the number of adverse classification outcomes of inspections

Senores pharma IPO subscribed 1.78 times on Day 1, retail demand strong

The initial share sale of Senores Pharmaceuticals Ltd got subscribed 1.78 times on Friday, the first day of bidding. The Initial Public Offer (IPO) received bids for 1,51,51,550 shares against 85,34,681 shares on offer, according to NSE data. Retail Individual Investors (RIIs) part fetched 7.19 times subscription while the quota for non-institutional investors got subscribed 1.67 times. Qualified Institutional Buyers (QIBs) quota got subscribed 1 per cent. Senores Pharmaceuticals Ltd on Thursday said it has secured nearly Rs 261 crore from anchor investors. The Rs 582-crore IPO will conclude on December 24. The IPO has a price range of Rs 372-391 per share. The Ahmedabad-based company's IPO is a combination of fresh issuance of shares worth Rs 500 crore and an offer for sale (OFS) of up to 21 lakh shares valued Rs 82.11 crore, by promoters and other selling shareholders, at the upper end of the price band. Proceeds from the fresh issue will be utilised for setting up a manufactur

Here's why Alembic Pharma was buzzing in trade on December 20, details here

Alembic Pharma share rose after the company announced that it has received final approval from the USFDA for its ANDA Divalproex Sodium Delayed-Release Capsules USP, 125 mg

Abbott India share rises 3% as JPMorgan ups target to Rs 31,500; details

The surge in Abbott India share price followed reports that JPMorgan, a New York-based financial services firm, raised its target price to Rs 31,500, up from Rs 30,000, signaling an upside of 12%

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Senores Pharma sets price band of Rs 372-391 for Rs 582 cr IPO to open Fri

Senores Pharmaceuticals Ltd on Wednesday said it has fixed a price band of Rs 372-391 per share for its Rs 582-crore initial public offering (IPO) that opens for subscription on December 20. The initial share-sale will conclude on December 24, the company announced. The Ahmedabad-based company's IPO is a combination of fresh issuance of shares worth Rs 500 crore and an offer for sale (OFS) of up to 21 lakh shares valued Rs 82.11 crore, by promoters and other selling shareholders, at the upper end of the price band. The public issue includes a reservation of 75,000 shares for employees. Proceeds from the fresh issue will be utilized for setting up a manufacturing facility for production of sterile injections in its Atlanta facility; funding the working capital requirements of the company and its subsidiaries, supporting inorganic growth through acquisition and other strategic initiatives and payment of debt. Besides, a portion will be used for general corporate purposes. The compan

Piramal Pharma up 7% as JM Financial initiates with 'Buy'; 36% upside eyed

The uptick in Piramal Pharma share price came after domestic brokerage JM Financial initiated coverage with 'Buy' for a target price of Rs 340

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Wockhardt gains 4% on filing for DCGI's approval for its insulin injection

Wockhardt is also developing additional insulin analogs and GLP-1 agonists to provide advanced diabetes care solutions

Lyka Labs shares rally 7% on CDSCO nod for diabetic neuropathy pain drug

Lyka Labs shares rose as the company announced that it has received the CDSCO approval for manufacturing & marketing of of Pregabalin Gel 8% w/w for use in patients with Diabetic Neuropathic Pain.

Indian pharma market registers over 5% growth in Sept 2024: Pharmarack

This comes even as the IPM registered a negative unit growth of -2.3 per cent, with only anti-diabetic and urology therapy segments recording significant unit growth of 3.1 per cent and 5.4 per cent